Polymatech IPO Plan 2026: ₹10,000 Crore Expansion Bet

Polymatech Electronics is preparing to file draft papers for a ₹10,000 crore IPO within the current calendar year, with the fundraise positioned as fuel for capacity expansion and a broader product push beyond chips. The company’s CEO has also indicated an aspirational valuation of about ₹1 lakh crore on a one-year forward basis, which is the framing being used to arrive at the proposed IPO size.

What Polymatech is planning

This proposed IPO is being positioned around two big shifts:

1. Scale-up of manufacturing and global footprint
   Polymatech already operates a multi-country setup across packaging, testing, PCB manufacturing, wafer/ingot work, and final assembly, and the IPO is being linked to expanding these capabilities.
   

2. Moving up the value chain
   The more strategic point is the company’s stated intent to evolve from being primarily a chip manufacturer into a broader electronics products company, which typically means higher value capture if executed well.
   

A quick look at the operating scale

Polymatech expects to close FY25 with around ₹2,000 crore in turnover, which provides context on the scale it is citing while planning a significantly larger IPO.

It is also worth noting that this is not the company’s first IPO attempt. Polymatech had filed draft papers for a ₹750 crore IPO in 2023, which was later postponed.

Where the money could go: capacity expansion and global build-out

The news outlines a company that is building a global operating map rather than a single-plant story. The footprint cited includes:

• Advanced semiconductor packaging facilities in India and Singapore

• A semiconductor testing plant in the US

• A printed circuit board (PCB) plant in Estonia

• An ingot and wafer facility in Grenoble, France

• A final product assembly unit in Bahrain
  

Alongside this, Polymatech has also been linked to a large Indian capex program. A notable example is its ₹1,143 crore project in Nava Raipur focused on gallium nitride (GaN) semiconductor manufacturing, which has been described as part of India’s push to reduce import dependence in critical chips.

The bigger strategic change: from “chip company” to “product company”

What makes this IPO story different from a standard “capacity expansion” narrative is the clear emphasis on forward integration.

Polymatech has recently forayed into medical devices manufacturing, launching a vein finder device built on its near-infrared LED platform. The company has stated it has received a registration certificate from CDSCO and has applied for European CE certification and US FDA approval for exports.

If this direction continues, investors will likely evaluate Polymatech on two separate tracks:

• The semiconductor/opto-chip lifecycle business (design to packaging and assembly)

• The ability to build repeatable product lines in regulated and competitive end markets like healthcare and consumer electronics
  

The company has also indicated an ambition to launch a new product every six months, and starting from FY27, each product line could target meaningful global revenue. This should be read as a stated ambition rather than an outcome, but it signals the strategy it wants markets to underwrite.

The pre-IPO funding round: what it signals

Alongside the IPO plan, the company is also looking to raise about $250 million through a pre-IPO funding round, with the CEO indicating inbound interest up to $1 billion from global investors. It has also indicated that term sheets are in late stages with investors across geographies, with a near-term timeline being discussed for finalisation.

Why this matters:

• A pre-IPO round can strengthen the balance sheet and fund near-term capex before public markets come in.

• It can also serve as an external validation point for valuation expectations, depending on who participates and at what terms.
  

Why this IPO will be watched closely

Even without the DRHP in the public domain yet, the story has a few elements that typically draw investor attention:

1) Semiconductor narrative + domestic manufacturing push

India’s semiconductor build-out is a long-cycle opportunity. Companies positioned across manufacturing, packaging, and downstream applications often attract attention because they sit inside a national priority theme.

2) Valuation expectations are already explicit

When a company communicates a target valuation (₹1 lakh crore one-year forward basis), it sets expectations early. Public market investors will then judge whether the scale, profitability trajectory, and product roadmap support that framing.

3) Product expansion changes the risk profile

Moving into medical devices and consumer electronics can expand revenue pools, but it also introduces new risks:

• Regulatory approvals and compliance burden

• Customer adoption and distribution execution

• Product quality and warranty liabilities

• Competitive dynamics that differ from component businesses
  

Key risks investors should keep in view

This news is expansion-heavy, so a balanced investor lens should include the key execution risks that typically show up in such transitions:

• Capital intensity and ramp-up risk
  Large capital expenditure (capex) programs require consistent execution, yield, and throughput improvements over time.
  

• Complexity from global footprint
  Multi-country operations introduce additional logistics and compliance complexity, particularly as volumes increase.
  

• Product-market execution risk
  Becoming a product company is not a linear upgrade. It requires brand building, distribution, after-sales support, and high reliability in regulated categories like healthcare.
  

• Valuation vs visibility gap
  If valuation targets run ahead of disclosure clarity, markets typically wait for DRHP-level detail before underwriting the story.
  

What to watch next

If you want to track this story like an investor rather than as a headline, these are the next real checkpoints:

1. DRHP filing and timing
   The company has indicated that the DRHP is being prepared and expected within the calendar year.
   

2. Merchant bankers and issue structure
   Who leads the issue and how the offer is structured (fresh issue vs offer for sale) will shape investor perception.
   

3. Pre-IPO round closure
   If the pre-IPO round closes, the terms and participant quality will matter more than the headline interest number.
   

4. Clarity on capex milestones
   Investors will look for hard timelines on plant ramp-up, product rollout cadence, and segment-level revenue contribution.
   

5. Public disclosures on the financial trajectory
   Once the DRHP is public, the focus will shift from ambition to measurable unit economics, margins, and cash flows.
   

Conclusion

Polymatech’s proposed ₹10,000 crore IPO is being positioned as a funding engine for a large expansion plan and a strategic move up the value chain into finished electronics products. It is an ambitious step, and the real investor debate will start once the public filing brings more details on the financial trajectory, offer structure, use of proceeds, and execution milestones.

If you want to track Polymatech unlisted shares more closely and monitor liquidity opportunities, you can do it through private-market platforms like Precize. Platforms like Precize add value by giving you access to private companies, enabling you to buy and sell unlisted and pre-IPO shares seamlessly.

Reserve access on Precize Today!